ID   Rh41
AC   CVCL_2176
SY   RH41; RH-41; Rh-41; SJ-Rh41
DR   CLO; CLO_0037075
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473491
DR   BioSample; SAMN10988473
DR   cancercelllines; CVCL_2176
DR   Cell_Model_Passport; SIDM00426
DR   Cosmic; 1620039
DR   Cosmic; 1718364
DR   Cosmic; 1995621
DR   Cosmic; 2820089
DR   Cosmic-CLP; 1240210
DR   DepMap; ACH-000100
DR   DSMZ; ACC-592
DR   DSMZCellDive; ACC-592
DR   EGA; EGAS00001000978
DR   GDSC; 1240210
DR   GEO; GSM219748
DR   GEO; GSM887538
DR   GEO; GSM888621
DR   GEO; GSM1670378
DR   GEO; GSM1676313
DR   GEO; GSM1701647
DR   LiGeA; CCLE_645
DR   LINCS_LDP; LCL-1415
DR   PharmacoDB; RH41_1313_2019
DR   PRIDE; PXD007755
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_2176
DR   Wikidata; Q54950346
RX   PubMed=11051265;
RX   PubMed=17471488;
RX   PubMed=19235922;
RX   PubMed=20922763;
RX   PubMed=22142829;
RX   PubMed=22460905;
RX   PubMed=23665679;
RX   PubMed=23882450;
RX   PubMed=26351324;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31448612;
RX   PubMed=31978347;
RX   PubMed=32758582;
RX   PubMed=35839778;
WW   https://www.cccells.org/PDF_Files/Rhabdomyosarcoma/Rh41%20Cell%20Line%20Data%20Sheet.pdf
WW   https://www.cccells.org/cellreqs-ncipptp.php
WW   http://www.pptpinvitro.org/cell_lines_panel.php
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 44 hours (PubMed=20922763); ~2-3 days (DSMZ=ACC-592); 60 hours (COG).
CC   HLA typing: A*68:01,68:01; B*14:02,40:01; C*01:04,03:04 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=17471488).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Exosome proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=1.24%; East Asian, South=0%; South Asian=0%; European, North=66.46%; European, South=32.3% (PubMed=30894373).
CC   Derived from site: Metastatic; Lung; UBERON=UBERON_0002048.
ST   Source(s): COG; Cosmic-CLP; DSMZ; PubMed=20922763
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 8,9
ST   D16S539: 12,13
ST   D18S51: 15,16
ST   D19S433: 13,15
ST   D21S11: 29,31
ST   D2S1338: 17,21
ST   D3S1358: 17
ST   D5S818: 10,13
ST   D7S820: 10,11
ST   D8S1179: 10,13
ST   FGA: 20,22
ST   Penta D: 9,12
ST   Penta E: 11,17
ST   TH01: 7,9.3
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C3749; Alveolar rhabdomyosarcoma
DI   ORDO; Orphanet_99756; Alveolar rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_5916 ! Rh4
SX   Female
AG   7Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 34
//
RX   PubMed=11051265;
RA   Petak I., Douglas L., Tillman D.M., Vernes R., Houghton J.A.;
RT   "Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced
RT   apoptosis and highly sensitive to TRAIL-induced apoptosis.";
RL   Clin. Cancer Res. 6:4119-4127(2000).
//
RX   PubMed=17471488; DOI=10.1002/path.2170;
RA   Lae M., Ahn E.H., Mercado G.E., Chuai S., Edgar M., Pawel B.R.,
RA   Olshen A., Barr F.G., Ladanyi M.;
RT   "Global gene expression profiling of PAX-FKHR fusion-positive alveolar
RT   and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.";
RL   J. Pathol. 212:143-151(2007).
//
RX   PubMed=19235922; DOI=10.1002/gcc.20655;
RA   Missiaglia E., Selfe J., Hamdi M., Williamson D., Schaaf G., Fang C.,
RA   Koster J., Summersgill B.M., Messahel B., Versteeg R.,
RA   Pritchard-Jones K., Kool M., Shipley J.M.;
RT   "Genomic imbalances in rhabdomyosarcoma cell lines affect expression
RT   of genes frequently altered in primary tumors: an approach to identify
RT   candidate genes involved in tumor development.";
RL   Genes Chromosomes Cancer 48:455-467(2009).
//
RX   PubMed=20922763; DOI=10.1002/pbc.22801;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
//
RX   PubMed=22142829; DOI=10.1158/1078-0432.CCR-11-2056;
RA   Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.-Y., Marchetti A.,
RA   Borsu L., Barr F.G., Ladanyi M.;
RT   "Oncogene mutation profiling of pediatric solid tumors reveals
RT   significant subsets of embryonal rhabdomyosarcoma and neuroblastoma
RT   with mutated genes in growth signaling pathways.";
RL   Clin. Cancer Res. 18:748-757(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23665679; DOI=10.1038/onc.2013.129;
RA   Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C.;
RT   "Proof-of-concept rare cancers in drug development: the case for
RT   rhabdomyosarcoma.";
RL   Oncogene 33:1877-1889(2014).
//
RX   PubMed=23882450; DOI=10.3389/fonc.2013.00183;
RA   Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G.,
RA   Linardic C.M.;
RT   "Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research:
RT   utility and pitfalls.";
RL   Front. Oncol. 3:183.1-183.12(2013).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31448612; DOI=10.1021/acs.jproteome.9b00157;
RA   Rammal G., Fahs A., Kobeissy F., Mechref Y., Zhao J.-F., Zhu R.,
RA   Diab-Assaf M., Saab R., Ghayad S.E.;
RT   "Proteomic profiling of rhabdomyosarcoma-derived exosomes yield
RT   insights into their functional role in paracrine signaling.";
RL   J. Proteome Res. 18:3567-3579(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=32758582; DOI=10.1016/j.gene.2020.145025;
RA   Batchu S., Kellish A.S., Hakim A.A.;
RT   "Assessing alveolar rhabdomyosarcoma cell lines as tumor models by
RT   comparison of mRNA expression profiles.";
RL   Gene 760:145025.1-145025.5(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//